logo
High Court partially allows Goh Jin Hian's appeal, finds he did not breach duty by not probing IPP's red flags

High Court partially allows Goh Jin Hian's appeal, finds he did not breach duty by not probing IPP's red flags

Business Times5 days ago

[SINGAPORE] The High Court has partially allowed an appeal by Goh Jin Hian, a former director of insolvent marine fuel supplier Inter-Pacific Petroleum (IPP).
The Appellate Division of the High Court ruled on Thursday (Jun 5) that Goh had breached his duty of care as a result of not being aware of IPP's cargo trading business – not because he had failed to open a probe into red flags surrounding the company.
The justices presiding were Tay Yong Kwang, Woo Bih Li and Kannan Ramesh.
Goh was also found not to have breached his duty to act in the best interests of IPP's creditors regarding drawdowns on bank facilities in relation to fraudulent cargo trades.
This follows his being found liable in February 2024 for breaching of his director's duties, statutory duties and the losses suffered by the firm, which came to US$146 million plus interest.
The liquidators of IPP had sued Dr Goh, the son of former prime minister Goh Chok Tong, to recover US$156 million in losses, accusing him of 'sleepwalking through his time as a director' and failing to discover and stop the drawdowns in trade financing between June 2019 and July 2019, said to have been funding non-existent or sham transactions.
BT in your inbox
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
Sign Up
Sign Up
In his grounds of decision released last July, High Court Justice Aedit Abdullah said Dr Goh had not taken 'reasonable steps', such as by making the necessary inquiries, when red flags surrounding the company arose.
Goh was also unaware of the existence of IPP's cargo trading business, despite being a director of the company, and therefore did not know this business was a fraudulent scheme perpetrated by IPP, said the justice.
Following the appeal, the judgement has been set aside, and Dr Goh no longer has to pay damages to IPP.
While the Court of Appeal agreed with the previous judgement that Goh had breached his duty of care by being unaware of IPP's cargo trading business, it found that the three red flags raised in the previous judgement were not 'red flags that would have put Dr Goh on a train of inquiry leading to the fraud in the cargo trading business being uncovered'.
One such red flag was an audit confirmation request relating to amounts of receivables due to IPP from customer Mercuria Energy Trading, which Goh signed and was sent to Mercuria on Feb 7, 2018. The sum due was US$132 million.
While Justice Aedit said Goh should have made inquiries upon receiving the audit confirmation request, the Court of Appeal said the fact that this sum was requested by Mercuria was 'not, in and of itself, enough to put him on inquiry'.
This was because Mercuria was a big company and that the size of the receivable could have been explained by IPP's sizeable trading volume, amounting to about US$1 billion, with it.
Two other issues that IPP's liquidators had called red flags – the suspension of IPP's bunker craft operator licence in June 2019 and three confirmations of indebtedness signed by Dr Goh in July 2019 – were also found not to be red flags by the Court of Appeal.
In the case of the suspension, 'even if Dr Goh had made the inquiries... it is unclear if he would have uncovered fraud in the cargo trading business, even if he had learned that IPP was carrying on such business'. The judges were not persuaded that the suspension of the licence was a red flag.
As for the confirmation of indebtedness, there was no assertion in the confirmations that the debts were for the cargo trading business, and they were thus not considered red flags.
The Court of Appeal therefore departed from Justice Aedit's finding that Dr Goh breached the care duty regarding the red flags.
The Court of Appeal also disagreed with Justice Aedit that Dr Goh did not breach his duty to act in the best interests of the respondent's creditors on the drawdowns for fraudulent cargo trades made on IPP's bank facilities.
It found that IPP bears the legal burden of proving that the fraud would have been detected, and that the resulting loss would have been averted had Dr Goh known that IPP was undertaking the cargo trading business, but failed to discharge this burden.
Dr Goh was represented by TSMP Law Corporation, led by joint managing partner Thio Shen Yi; IPP's liquidators were represented by LVM Law Chambers, led by managing director Lok Vi Ming.
After the appeal, Thio said the decision has practical implications for all directors, as the Court of Appeal has clarified that it 'cannot be part of a director's duty of supervision and oversight to pick up fraud unless there are tell-tale warning signs'.
'Directors owe fiduciary obligations and the duty of care to the company, but the Appeals Court has crucially recognised the practical and commercial limits to their ability to scrutinise for and detect fraud, especially deep-seated fraud,' he added.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

US, China begin key trade talks in London
US, China begin key trade talks in London

Straits Times

time4 hours ago

  • Straits Times

US, China begin key trade talks in London

US Secretary of Treasury Scott Bessent and Chinese Vice-Premier He Lifeng shake hands as they pose for a photo during trade talks at the Lancaster House in London. PHOTO: AFP LONDON - China and the United States began a new round of trade talks in London on June 9, Beijing's state media reported, as the world's two biggest economies seek to shore up a shaky truce after bruising tit-for-tat tariffs. The two sides are meeting in the historic Lancaster House, run by the UK Foreign Office, following a first round of talks in Geneva in May. Chinese Vice-Premier He Lifeng was again heading the team in London. Chinese state news agency Xinhua reported the start of the talks. Treasury Secretary Scott Bessent, Commerce Secretary Howard Lutnick and Trade Representative Jamieson Greer are leading the US delegation, President Donald Trump said on June 6. 'The meeting should go very well,' Mr Trump said on his Truth Social platform. His press secretary, Karoline Leavitt, told Fox News on June 8: 'We want China and the United States to continue moving forward with the agreement that was struck in Geneva.' While the UK government reiterated that it was not involved in the discussions, a spokesperson said: 'We are a nation that champions free trade.' UK authorities 'have always been clear that a trade war is in nobody's interests, so we welcome these talks', the spokesperson added. Rare earths The talks in London come just a few days after Mr Trump and Chinese President Xi Jinping finally held their first publicly announced telephone talks since the Republican returned to the White House. Mr Trump said June 5's call reached a 'very positive conclusion'. Mr Xi was quoted by Xinhua as saying 'correcting the course of the big ship of Sino-US relations requires us to steer well and set the direction'. Tensions between the two nations have soared, with Mr Trump accusing Beijing of violating a tariff de-escalation deal reached in Geneva in mid-May. (From left to right) US Trade Representative Jamieson Greer, US Secretary of Commerce Howard Lutnick, US Secretary of Treasury Scott Bessent, Chinese Vice-Premier He Lifeng, Chinese Commerce Minister Wang Wentao, and Chinese International Trade Representative and Vice-Minister of Commerce Li Chenggang, posing for a photo at the Lancaster House on June 9. PHOTO: AFP 'We need China to comply with their side of the deal. And so that's what the trade team will be discussing tomorrow,' Ms Leavitt said on June 8. A key issue will be Beijing's shipments of rare earths – crucial to a range of goods including electric vehicle batteries and which have been a bone of contention for some time. 'Rare earth shipments from China to the US have slowed since President Trump's 'Liberation Day' tariffs in April,' said Ms Kathleen Brooks, research director at trading group XTB. 'The US wants these shipments to be reinstated, while China wants the US to rethink immigration curbs on students, restrictions on access to advanced technology including microchips, and to make it easier for Chinese tech providers to access US consumers,' she added. In April, Mr Trump introduced sweeping worldwide tariffs that targeted China most heavily. At one point, Washington hit Beijing with additional levies of 145 per cent on its goods, prompting China to respond with tariffs reaching 125 per cent on US goods. After two days of talks in Switzerland, both sides agreed to slash the eye-watering tariffs for 90 days, but key differences remain – especially over China's rare earth export restrictions. The impact was reflected in the latest official export data released on June 9 in Beijing. Exports to the United States fell 12.7 per cent in May from the previous month, with China shipping US$28.8 billion (S$37 billion) worth of goods. This was down from US$33 billion in April, according to Beijing's General Administration of Customs. 'Green channel' Throughout its talks with Washington, China has also launched discussions with other trading partners – including Japan and South Korea – to try to build a united front to counter Mr Trump's tariffs. On June 5, Beijing and Canada agreed to regularise their channels of communication after strained ties. Beijing has also proposed establishing a 'green channel' to ease exports of rare earths to the European Union, and fast-tracking approval of some export licenses. China is expected to host a summit with the EU in July, marking 50 years since Beijing and Brussels established diplomatic ties. According to a spokesperson for Mr Starmer, Britain's finance minister Rachel Reeves took advantage of the talks in London to meet with her US counterpart Scott Bessent and Chinese Vice-Premier He Lifeng on June 8. AFP Join ST's Telegram channel and get the latest breaking news delivered to you.

US-China trade talks in London hang over markets
US-China trade talks in London hang over markets

Business Times

time6 hours ago

  • Business Times

US-China trade talks in London hang over markets

[LONDON] US-China trade talks in London held markets' attention on Monday (Jun 9), with Asian stocks rising, Wall Street mixed and Europe dipping. The London negotiations, following on from a first round in Geneva last month, aim to quell renewed tariff tensions between Washington and Beijing. New York's Dow and S&P 500 indices were lower, while the tech-heavy Nasdaq rose slightly in early trading. Asian shares closed up on hopes of a deal, and catching up with Wall Street from Friday, when US jobs data suggested the American economy was doing well, for now. The US dollar, however, was largely unmoved, with persistent fears of higher US inflation in the pipeline from Trump's generalised tariffs weighing on it. London, Paris and Frankfurt indices were all lower. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up While the US economy was showing resilience, official data on Monday showed China's exports to the US last month grew at a slower pace than expected, even as they picked up to the EU and Asia. The US-China talks took place following a call between US President Donald Trump and Chinese President Xi Jinping last Thursday. They sought a de-escalation after each had accused the other of violating terms of a tariffs reprieve struck in Geneva in mid-May. The US side in London on Monday was being led by Treasury Secretary Scott Bessent, Commerce Secretary Howard Lutnick and Trade Representative Jamieson Greer, while Vice Premier He Lifeng headed the Chinese team. Their meeting was helped by news that Beijing on Saturday approved some applications for rare-earth exports, while US aviation giant Boeing is to start sending commercial jets to China for the first time since April. Easing China's export controls on rare-earths was key for Washington, 'while China wants the US to rethink immigration curbs on students, restrictions on access to advanced technology including microchips, and to make it easier for Chinese tech providers to access US consumers,' said Kathleen Brooks, research director at XTB. 'The outcome of these discussions will be crucial for market sentiment,' she said. The US dollar's weakness came as economists warned that Trump's tariffs on most of the world could reignite inflation, and as the US Federal Reserve weighs whether to lower interest rates. 'The May minutes and recent comments by several (policy board) members... suggest the Fed is highly attentive to the risk that tariffs will lead to a persistent inflation shock,' wrote analysts at Bank of America. In corporate news, entertainment giant Warner Bros Discovery announced plans to split into two publicly traded companies, sending its share price higher by more than 9 per cent. One would be a Streaming and Studios company covering film and TV production and catalogues, and the other a Global Network company with television brands including CNN and Discovery, and free-to-air channels in Europe. US semiconductor maker Qualcomm also announced it was buying a UK firm, Alphawave, for US$2.4 billion as demand for database infrastructure heated up from demand in the AI sector. Alphawave shares in London jumped more than 22 per cent on the news. Qualcomm's shares rose three per cent in New York. AFP

Asia healthcare assets risk overvaluation as private investors scoop them up
Asia healthcare assets risk overvaluation as private investors scoop them up

Business Times

time8 hours ago

  • Business Times

Asia healthcare assets risk overvaluation as private investors scoop them up

[SINGAPORE] As private equity (PE) investors pour money into Asian healthcare, some observers are concerned that this sector could soon overheat. Some recent deals this year include KKR's US$400 million purchase of a 54 per cent stake in India's Healthcare Global Enterprises in February. In Singapore, another American PE firm TPG took Catalist-listed nursing operator Econ Healthcare private in a deal worth nearly S$88 million. When the proposed transaction was announced in February, the offer price represented a 20 per cent premium to Econ's last traded share price on Jan 14. 'We are not the only ones to see the opportunity of healthcare in Asia, and, as a consequence, valuations can be high,' Abrar Mir, co-founder and managing partner of healthcare-focused PE firm Quadria Capital, told The Business Times. Other factors driving investors to the healthcare sector – perceived as defensive, and so able to withstand the ups and downs of economic cycles – is the ongoing macroeconomic uncertainty and volatility in global financial markets. This is particularly so in Asia, where investors have been diversifying away from China in the last few years, to avoid being caught in the cross hairs of the nation's tensions with the United States. As PE firms and their investors focus on acquiring companies independent of China, more deals have been transacted in Japan, South Korea and India, where the demand for healthcare and related services is strong and largely unaffected by tariffs. 'Japan has always been a stable healthcare market, and particularly because of (its) demographics and medical needs,' said David Braga Malta, thematic health principal at Pictet Alternative Advisors, to BT. 'We saw some of the mid-sized Japanese pharma companies being very acquisitive in the recent months and years... And of course, we saw the boom in the IPO (initial public offering) markets in India last year.' BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Asia's appeal even drew European PE investors to buy South Korean assets for the first time in 2024, he added. Last September, France's Archimed spent US$742 million buying Jeisys Medical, a South Korean developer of aesthetic medicine devices. Like shopping in Louis Vuitton 'One of the key things that I always say to my investors is that... investing in healthcare in Asia is like shopping in Louis Vuitton. So, as an investor, we have to navigate that, be careful not to overpay,' said Quadria Capital's Mir. According to a Bain & Co report, global PE deal value in the sector surged last year to an estimated US$115 billion – the second highest on record. Bain added that PE firms continue to invest in healthcare in the Asia-Pacific, where deal values have been steadily rising since 2016. Industry participants named India as the country attracting the most number of healthcare PE investors. An ageing population, rising incidence of chronic disease and growing awareness of preventive care, combined with the opening up of its insurance market to foreign investment, are making India stand out. Bain estimated that the country made up 26 per cent of the 62 deals transacted in the Asia-Pacific last year. PwC said its health industries practice in India hit a double-digit compound annual growth rate in the past few years as well. But Ling Tok Hong, deals and private equity leader at PwC, cautioned that 'this continued focus on the India market could make it more susceptible to overvaluation if investors are not cautious'. South-east Asia's healthcare sector is also attracting PE investors, leading to 'unprecedented valuations' of Ebitda multiples in their 20s, noted Ling. He was referring to earnings before interest, taxes, depreciation and amortisation. Room for growth; returns still strong Despite the rising valuations in Asia's healthcare sector, market participants point out that there is still room for growth, a key factor backing the higher valuations in the first place. The sector offers attractive long-term growth prospects as the supply of quality healthcare assets in the region is not growing quickly enough to meet demand. In markets such as South-east Asia, 'the number of large, institutionally ready platforms is still limited. This scarcity has helped sustain high entry multiples in recent years', said Alex Boulton, partner and Asia-Pacific lead for healthcare and life sciences private equity at Bain. He pointed out that South-east Asia's healthcare sector relies heavily on private players. For instance, the private sector accounts for roughly half of all hospital beds in Indonesia and the Philippines. 'That structural dynamic creates an enduring role for private capital in expanding and upgrading healthcare infrastructure.' Market participants emphasise that Asian healthcare is not in bubble territory. Boulton pointed out that even with rising valuations, healthcare PE in Asia is still delivering strong returns. Bain's analysis shows that from 2018 to 2023, the median multiple on invested capital (MOIC) for exited healthcare deals in the region was approximately 2.6 – meaning that a US$1 million investment generated a return of US$2.6 million. This compares with the global median MOIC of around two. 'That speaks to the sector's ability to compound value through growth and operational improvement, even in a more expensive entry environment,' noted Boulton. That said, while returns are likely to remain strong in the future, the median MOIC may not be sustained at these levels, he added. Thus, market players said, investors will need to have a clear plan to create meaningful impact and value over the life of their investments.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store